Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Bad news for Novo Nordisk (NVO 4.37%) Friday was good news for Eli Lilly (LLY 3.71%) and Viking Therapeutics (VKTX 0.17%), its two main rivals in the field of weight loss drugs. This morning ...

Novo Nordisk's stock dives toward biggest loss in more than 20 years, while rival Eli Lilly's stock jumps The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Despite the miss, CagriSema's results are competitive ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

This agreement grants Novo Nordisk an exclusive license to develop and market products targeting obesity and type 2 diabetes, with Ascendis set to receive a $100 million milestone payment ...